The estimated Net Worth of Mark Throsby is at least $2.32 Million dollars as of 7 July 2020. Mark Throsby owns over 368 units of Merus N.V stock worth over $2,288,494 and over the last 5 years Mark sold MRUS stock worth over $26,945.
Mark has made over 13 trades of the Merus N.V stock since 2020, according to the Form 4 filled with the SEC. Most recently Mark sold 368 units of MRUS stock worth $5,689 on 7 July 2020.
The largest trade Mark's ever made was exercising 87,621 units of Merus N.V stock on 24 February 2020 worth over $4,405,584. On average, Mark trades about 6,744 units every 13 days since 2020. As of 7 July 2020 Mark still owns at least 45,515 units of Merus N.V stock.
You can see the complete history of Mark Throsby stock trades at the bottom of the page.
Mark's mailing address filed with the SEC is C/O MERUS N.V., YALELAAN 62, UTRECHT, P7, 3584 CM.
Over the last 5 years, insiders at Merus N.V have traded over $76,701,272 worth of Merus N.V stock and bought 4,110,523 units worth $71,063,751 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... und Corp Incyte. On average, Merus N.V executives and independent directors trade stock every 18 days with the average trade being worth of $4,323,728. The most recent stock trade was executed by Harry Shuman on 20 August 2024, trading 5,000 units of MRUS stock currently worth $251,400.
merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Merus N.V executives and other stock owners filed with the SEC include: